Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-04-15

AUTHORS

P. M. Clarke, A. M. Gray, A. Briggs, R. J. Stevens, D. R. Matthews, R. R. Holman, on behalf of the UK Prospective Diabetes Study (UKPDS)

ABSTRACT

Aims/hypothesisThis study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.MethodsWe conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.ResultsThe incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was £6,028, and for blood pressure control was £369. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.Conclusions/interpretationEach of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions. More... »

PAGES

868-877

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3

DOI

http://dx.doi.org/10.1007/s00125-005-1717-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003605836

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15834550


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Costs and Cost Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Complications", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia", 
          "id": "http://www.grid.ac/institutes/grid.415193.b", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK", 
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "P. M.", 
        "id": "sg:person.0734456474.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "A. M.", 
        "id": "sg:person.01307325071.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Briggs", 
        "givenName": "A.", 
        "id": "sg:person.01142063040.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142063040.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stevens", 
        "givenName": "R. J.", 
        "id": "sg:person.01052527755.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matthews", 
        "givenName": "D. R.", 
        "id": "sg:person.01216556762.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216556762.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK", 
            "Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holman", 
        "givenName": "R. R.", 
        "id": "sg:person.01017043005.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "on behalf of the UK Prospective Diabetes Study (UKPDS)", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s001250051617", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001128875", 
          "https://doi.org/10.1007/s001250051617"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00400195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022043816", 
          "https://doi.org/10.1007/bf00400195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4612-1304-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007161826", 
          "https://doi.org/10.1007/978-1-4612-1304-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-004-1527-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036304902", 
          "https://doi.org/10.1007/s00125-004-1527-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-04-15", 
    "datePublishedReg": "2005-04-15", 
    "description": "Aims/hypothesisThis study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.MethodsWe conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.ResultsThe incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was \u00a36,028, and for blood pressure control was \u00a3369. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.Conclusions/interpretationEach of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00125-005-1717-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6719947", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "48"
      }
    ], 
    "keywords": [
      "intensive blood glucose control", 
      "tight blood pressure control", 
      "blood pressure control", 
      "blood glucose control", 
      "type 2 diabetes", 
      "quality-adjusted life years", 
      "UK Prospective Diabetes Study", 
      "glucose control", 
      "cost-utility analysis", 
      "pressure control", 
      "life years", 
      "metformin therapy", 
      "healthcare resources", 
      "type 2 diabetic patients", 
      "hospital-based clinics", 
      "patient-level data", 
      "intensive blood glucose", 
      "Prospective Diabetes Study", 
      "UKPDS Outcomes Model", 
      "care of patients", 
      "quality-adjusted life expectancy", 
      "overweight patients", 
      "hypertensive patients", 
      "diabetic patients", 
      "Diabetes Study", 
      "blood glucose", 
      "patients", 
      "diabetes", 
      "trial effects", 
      "incremental cost", 
      "effectiveness ratio", 
      "life expectancy", 
      "therapy", 
      "outcome model", 
      "years", 
      "hypertension", 
      "control", 
      "metformin", 
      "clinic", 
      "MethodsWe", 
      "insulin", 
      "trials", 
      "net cost", 
      "care", 
      "intervention", 
      "study", 
      "glucose", 
      "expectancy", 
      "rationale", 
      "Northern Ireland", 
      "levels", 
      "effect", 
      "analysis", 
      "data", 
      "effectiveness", 
      "ratio", 
      "results", 
      "England", 
      "Scotland", 
      "cost", 
      "part", 
      "Ireland", 
      "uses", 
      "economic rationale", 
      "economic efficiency", 
      "different policies", 
      "model", 
      "policy", 
      "low cost", 
      "terms", 
      "resources", 
      "corresponds", 
      "lifetime", 
      "efficiency", 
      "Aims/hypothesisThis study", 
      "hypothesisThis study", 
      "sulphonylurea/insulin", 
      "Conclusions/interpretationEach", 
      "interpretationEach", 
      "type 2 diabetes corresponds", 
      "diabetes corresponds"
    ], 
    "name": "Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)", 
    "pagination": "868-877", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003605836"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00125-005-1717-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15834550"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00125-005-1717-3", 
      "https://app.dimensions.ai/details/publication/pub.1003605836"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_408.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00125-005-1717-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00125-005-1717-3'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      22 PREDICATES      125 URIs      113 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00125-005-1717-3 schema:about N085d6166673b4819885e7d7f40b983ae
2 N17cba14e9352421ab32d96e1f4cd9ca1
3 N2a5260594d21482c93187d878cebcc6d
4 N4dfce1bb9917475d9f7fbe41ea965aef
5 N68f3a7b2e5f54671b371a0f40ae43c64
6 N6c4b0bb0d9434ce8be99216248330cb4
7 N963c232c2bd841ca9b7e8483bb8ec214
8 Na0aed9803f954c02bc05f3abd5de8675
9 Na2e670bce9ae41e5ba8ef64e33451897
10 Nc194444c420946aca43e981794ea88d5
11 Ne6723692aa664bf2b538ad4baa7a6497
12 Ned1b9a3f912c4eb0873ee25350bf7208
13 Nfc8754f648c44c258f1cf4dbafaee961
14 Nff04821b62c349d3986e6f4e93f9edf4
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N1c7a760eb1c340649badf7f4853274f4
18 schema:citation sg:pub.10.1007/978-1-4612-1304-8
19 sg:pub.10.1007/bf00400195
20 sg:pub.10.1007/s00125-004-1527-z
21 sg:pub.10.1007/s001250051617
22 schema:datePublished 2005-04-15
23 schema:datePublishedReg 2005-04-15
24 schema:description Aims/hypothesisThis study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight.MethodsWe conducted cost-utility analysis based on patient-level data from a randomised clinical controlled trial involving 4,209 patients with newly diagnosed type 2 diabetes conducted in 23 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). Three different policies were evaluated: intensive blood glucose control with sulphonylurea/insulin; intensive blood glucose control with metformin for overweight patients; and tight blood pressure control of hypertensive patients. Incremental cost : effectiveness ratios were calculated based on the net cost of healthcare resources associated with these policies and on effectiveness in terms of quality-adjusted life years gained, estimated over a lifetime from within-trial effects using the UKPDS Outcomes Model.ResultsThe incremental cost per quality-adjusted life years gained (in year 2004 UK prices) for intensive blood glucose control was £6,028, and for blood pressure control was £369. Metformin therapy was cost-saving and increased quality-adjusted life expectancy.Conclusions/interpretationEach of the three policies evaluated has a lower cost per quality-adjusted life year gained than that of many other accepted uses of healthcare resources. The results provide an economic rationale for ensuring that care of patients with type 2 diabetes corresponds at least to the levels of these interventions.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N96bfc887f1b14a2a801618c009ef4f91
29 Nc3e8399525ed42c79d79d9838e63a9df
30 sg:journal.1001482
31 schema:keywords Aims/hypothesisThis study
32 Conclusions/interpretationEach
33 Diabetes Study
34 England
35 Ireland
36 MethodsWe
37 Northern Ireland
38 Prospective Diabetes Study
39 Scotland
40 UK Prospective Diabetes Study
41 UKPDS Outcomes Model
42 analysis
43 blood glucose
44 blood glucose control
45 blood pressure control
46 care
47 care of patients
48 clinic
49 control
50 corresponds
51 cost
52 cost-utility analysis
53 data
54 diabetes
55 diabetes corresponds
56 diabetic patients
57 different policies
58 economic efficiency
59 economic rationale
60 effect
61 effectiveness
62 effectiveness ratio
63 efficiency
64 expectancy
65 glucose
66 glucose control
67 healthcare resources
68 hospital-based clinics
69 hypertension
70 hypertensive patients
71 hypothesisThis study
72 incremental cost
73 insulin
74 intensive blood glucose
75 intensive blood glucose control
76 interpretationEach
77 intervention
78 levels
79 life expectancy
80 life years
81 lifetime
82 low cost
83 metformin
84 metformin therapy
85 model
86 net cost
87 outcome model
88 overweight patients
89 part
90 patient-level data
91 patients
92 policy
93 pressure control
94 quality-adjusted life expectancy
95 quality-adjusted life years
96 ratio
97 rationale
98 resources
99 results
100 study
101 sulphonylurea/insulin
102 terms
103 therapy
104 tight blood pressure control
105 trial effects
106 trials
107 type 2 diabetes
108 type 2 diabetes corresponds
109 type 2 diabetic patients
110 uses
111 years
112 schema:name Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
113 schema:pagination 868-877
114 schema:productId N32d7c469f2214dfbae4bfb129c1bdcd7
115 N62991b73cc5b4c4fb913cd761805a97e
116 Na91c1366cebc4045a01be70bac0e6f9c
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003605836
118 https://doi.org/10.1007/s00125-005-1717-3
119 schema:sdDatePublished 2021-11-01T18:08
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher Nec287ec521bb4bee86f2abf8b59cae9f
122 schema:url https://doi.org/10.1007/s00125-005-1717-3
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N085d6166673b4819885e7d7f40b983ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Middle Aged
128 rdf:type schema:DefinedTerm
129 N17cba14e9352421ab32d96e1f4cd9ca1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name United Kingdom
131 rdf:type schema:DefinedTerm
132 N1c7a760eb1c340649badf7f4853274f4 rdf:first sg:person.0734456474.38
133 rdf:rest Naad53d9569264c2e98d0b7467f6ebb63
134 N2a5260594d21482c93187d878cebcc6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Blood Pressure
136 rdf:type schema:DefinedTerm
137 N32d7c469f2214dfbae4bfb129c1bdcd7 schema:name pubmed_id
138 schema:value 15834550
139 rdf:type schema:PropertyValue
140 N4dfce1bb9917475d9f7fbe41ea965aef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Blood Glucose
142 rdf:type schema:DefinedTerm
143 N57ed9ed2be6d46a28114214d7a1b2a22 rdf:first sg:person.01017043005.08
144 rdf:rest Nc8f0a6330c9a476eb6e3d8556ecb4cba
145 N5c9640139501487985fd19cad794f446 rdf:first sg:person.01142063040.42
146 rdf:rest Na8eec31c30d049beb26292ce59a1c647
147 N62991b73cc5b4c4fb913cd761805a97e schema:name doi
148 schema:value 10.1007/s00125-005-1717-3
149 rdf:type schema:PropertyValue
150 N68f3a7b2e5f54671b371a0f40ae43c64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Antihypertensive Agents
152 rdf:type schema:DefinedTerm
153 N6c4b0bb0d9434ce8be99216248330cb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Costs and Cost Analysis
155 rdf:type schema:DefinedTerm
156 N71c405348d3e4480b64e6fac45981d38 schema:familyName on behalf of the UK Prospective Diabetes Study (UKPDS)
157 rdf:type schema:Person
158 N963c232c2bd841ca9b7e8483bb8ec214 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Hypoglycemic Agents
160 rdf:type schema:DefinedTerm
161 N96bfc887f1b14a2a801618c009ef4f91 schema:volumeNumber 48
162 rdf:type schema:PublicationVolume
163 Na0aed9803f954c02bc05f3abd5de8675 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Diabetes Mellitus, Type 2
165 rdf:type schema:DefinedTerm
166 Na2e670bce9ae41e5ba8ef64e33451897 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Diabetes Complications
168 rdf:type schema:DefinedTerm
169 Na8eec31c30d049beb26292ce59a1c647 rdf:first sg:person.01052527755.23
170 rdf:rest Nd3c19fbddcca494689166c48ff3f8fd1
171 Na91c1366cebc4045a01be70bac0e6f9c schema:name dimensions_id
172 schema:value pub.1003605836
173 rdf:type schema:PropertyValue
174 Naad53d9569264c2e98d0b7467f6ebb63 rdf:first sg:person.01307325071.02
175 rdf:rest N5c9640139501487985fd19cad794f446
176 Nc194444c420946aca43e981794ea88d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Humans
178 rdf:type schema:DefinedTerm
179 Nc3e8399525ed42c79d79d9838e63a9df schema:issueNumber 5
180 rdf:type schema:PublicationIssue
181 Nc8f0a6330c9a476eb6e3d8556ecb4cba rdf:first N71c405348d3e4480b64e6fac45981d38
182 rdf:rest rdf:nil
183 Nd3c19fbddcca494689166c48ff3f8fd1 rdf:first sg:person.01216556762.76
184 rdf:rest N57ed9ed2be6d46a28114214d7a1b2a22
185 Ne6723692aa664bf2b538ad4baa7a6497 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Aged
187 rdf:type schema:DefinedTerm
188 Nec287ec521bb4bee86f2abf8b59cae9f schema:name Springer Nature - SN SciGraph project
189 rdf:type schema:Organization
190 Ned1b9a3f912c4eb0873ee25350bf7208 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Cost-Benefit Analysis
192 rdf:type schema:DefinedTerm
193 Nfc8754f648c44c258f1cf4dbafaee961 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Adult
195 rdf:type schema:DefinedTerm
196 Nff04821b62c349d3986e6f4e93f9edf4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Hypertension
198 rdf:type schema:DefinedTerm
199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
200 schema:name Medical and Health Sciences
201 rdf:type schema:DefinedTerm
202 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
203 schema:name Clinical Sciences
204 rdf:type schema:DefinedTerm
205 sg:grant.6719947 http://pending.schema.org/fundedItem sg:pub.10.1007/s00125-005-1717-3
206 rdf:type schema:MonetaryGrant
207 sg:journal.1001482 schema:issn 0012-186X
208 1432-0428
209 schema:name Diabetologia
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.01017043005.08 schema:affiliation grid-institutes:grid.4991.5
213 schema:familyName Holman
214 schema:givenName R. R.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08
216 rdf:type schema:Person
217 sg:person.01052527755.23 schema:affiliation grid-institutes:grid.4991.5
218 schema:familyName Stevens
219 schema:givenName R. J.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23
221 rdf:type schema:Person
222 sg:person.01142063040.42 schema:affiliation grid-institutes:grid.4991.5
223 schema:familyName Briggs
224 schema:givenName A.
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142063040.42
226 rdf:type schema:Person
227 sg:person.01216556762.76 schema:affiliation grid-institutes:grid.4991.5
228 schema:familyName Matthews
229 schema:givenName D. R.
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216556762.76
231 rdf:type schema:Person
232 sg:person.01307325071.02 schema:affiliation grid-institutes:grid.4991.5
233 schema:familyName Gray
234 schema:givenName A. M.
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02
236 rdf:type schema:Person
237 sg:person.0734456474.38 schema:affiliation grid-institutes:grid.415193.b
238 schema:familyName Clarke
239 schema:givenName P. M.
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38
241 rdf:type schema:Person
242 sg:pub.10.1007/978-1-4612-1304-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007161826
243 https://doi.org/10.1007/978-1-4612-1304-8
244 rdf:type schema:CreativeWork
245 sg:pub.10.1007/bf00400195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022043816
246 https://doi.org/10.1007/bf00400195
247 rdf:type schema:CreativeWork
248 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
249 https://doi.org/10.1007/s00125-004-1527-z
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s001250051617 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001128875
252 https://doi.org/10.1007/s001250051617
253 rdf:type schema:CreativeWork
254 grid-institutes:grid.415193.b schema:alternateName Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia
255 schema:name Australian Centre for Diabetes Strategies, Prince of Wales Hospital, Sydney, Australia
256 Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
257 Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK
258 rdf:type schema:Organization
259 grid-institutes:grid.4991.5 schema:alternateName Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK
260 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
261 schema:name Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
262 Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, OX3 7LF, Oxford, UK
263 Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...